The CRISPR field produced divergent headlines this week: CRISPR Therapeutics reported early clinical data showing substantial reductions in cholesterol and triglycerides with an investigational in vivo editing therapy, while Intellia disclosed a patient death and an FDA clinical‑hold letter for its MAGNITUDE Phase III program. Industry coverage framed the juxtaposition as a reminder of both rapid therapeutic progress and persistent safety risks. Company releases and conference presentations supply the clinical details: CRISPR Therapeutics’ early lipid results were presented at AHA and show potential for one‑time interventions in cardiometabolic disease, whereas Intellia is cooperating with regulators on a fatal adverse event that followed liver injury. Investors and developers said the week reinforces the need for robust safety monitoring in systemic gene editing programs.